Interleukin-12 induces an effective antitumor response in malignant mesothelioma

American Journal of Respiratory Cell and Molecular Biology

Volumn 19, Issue 5, 1998, Pages 738-746

  Caminschi, Irina ^a   Venetsanakos, Eleni ^a   Leong, Clement C ^a   Garlepp, Michael J ^a   Scott, Bernadette ^a   Robinson, Bruce W S ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MURINAE;

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CELL CULTURE; CELL DIVISION; DISEASE MODEL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETIC TRANSFECTION; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MESOTHELIOMA; MOUSE; NATURAL KILLER CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CELL DIVISION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; MESOTHELIOMA; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032209532     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.19.5.3257m     Document Type: Article

References (51)

1. Lilienfeld, D. E., J. S. Mandel, P. Coin, and L. M. Schuman. 1988. Projection of asbestos related diseases in the United States. 1985-2009: I. Cancer. Br. J. Ind. Med. 45:283-291.
2. Robinson, B. W. S., M. J. Garlepp, and B. Scott. 1995. Mesothelioma. In The Lung: Scientific Foundations, 2nd ed. R. G. Crystal and J. B. West, editors. Raven Press, New York. 2599-2610.
3. Musk, A. W., N. H. deKlerk, J. L. Eccles, and M. T. Lotze. 1992. Wittennoom, Western Australia: a modern industrial disaster. Am. J. Indust. Med. 21:735-747.
4. Musk, A. W., and S. D. Woodward. 1982. Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust. N.Z. J. Med. 12:229-232.
5. Manning, L. S., A. H. Rose, R. V. Bowman, T. I. Christmas, M. J. Garlepp, and B. W. S. Robinson. 1992. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In Malignant Mesothelioma. D. W. S. Henderson, K. Shilkin, S. Langlois, and D. Whitaker, editors. Hemisphere Publishing Corporation, New York. 278-291.
6. Manning, L. S., R. V. Bowman, S. B. Darby, and B. W. Robinson. 1989. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am. Rev. Respir. Dis. 139:1369-1374.
7. Christmas, T. I., L. S. Manning, M. J. Garlepp, A. W. Musk, and B. W. Robinson. 1993. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:9-12.
8. Davis, M. R., L. S. Manning, D. Whitaker, M. J. Garlepp, and B. W. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52:881-886.
9. Manning, L. S., D. Whitaker, A. R. Murch, M. J. Garlepp, M. R. Davis, A. W. Musk, and B. W. Robinson. 1991. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer 47:285-290.
10. Gately, M. K., A. G. Wolitzky, P. M. Quinn, and R. Chizzonite. 1992. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143:127-142.
11. Kobayasi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
12. Zeh, H. J., III. S. Hurd, W. J. Storkus, and M. T. Lotze. 1993. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunol. 14:155-161.
13. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin-12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199-1204.
14. Chan, S. H., M. Kobayashi, D. Santoli, B. Perussia, and G. Trinchieri. 1992. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J. Immunol, 148:92-98.
15. Aste-Amezaga, M., A. D'Andrea, M. Kubin, and G. Trinchieri. 1994. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol. 156:480-492.
16. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178:1223-1230.
17. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, and M. T. Lotze. 1994. Recombinant 1L-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 153:1697-1706.
18. Mu, J., J. P. Zou, N. Yamamoto, T. Tsutsui, X. G. Tai, M. Kobayashi, S. Herrmann, H. Fujiwara, and T. Hamaoka. 1995. Administration of recombinant interleukin-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55:4404-4408.
19. Zou, J. P., N. Yamamoto, T. Fujii, H. Takenaka, M. Kobayashi, S. H. Herrmann, S. F. Wolf, H. Fujiwara, and T. Hamaoka. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int. Immunol. 7:1135-1145.
20. Coughlin, C. M., M. Wysocka, H. L. Kurzawa, W. M. Lee, G. Trinchieri, and S. L. Eck. 1995. B7-1 and interleukin-12 synergistically induce effective antitumor immunity. Cancer Res. 55:4980-4987.
21. Noguchi, Y., E. C. Richards, Y. T. Chen, and L. J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Nat. Acad. Sci. USA 92:2219-2223.
22. Rao, J. B., R. S. Chamberlain, V. Bronte, M. W, Carroll, K. R. Irvine, B. Moss. S. A. Rosenborg, and N. P. Restifo. 1996. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 156:3357-3365.
23. Roth, J. A., and R. J. Cristiano. 1997, Gene therapy for cancer - what have we done and where are we going? J. Nat. Cancer Inst. 89:21-39.
24. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Propero, and H. Waldman. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 312:548-551.
25. Leong, C., J. Marley, S. Loh, B. Robinson, and M. Garlepp. 1996. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. Cancer Gene Ther. 3:321-330.
26. Bielefeldt-Ohmann, H., D. R. Fitzpatrick, A. L. Marzo, A. G. Jarnicki, R. P. Himbeck, M. R. Davis, L. S. Manning, and B. W. Robinson. 1994. Pathoand immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol. Immunother. 39:347-359.
27. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270:908.
28. Sulitzeanu, D. 1993. Immunosuppressive factors in human cancer. Adv. Can. Res. 60:247-267.
29. Onrust, S. V., P. M. Hartl, S. D. Rosen, and D. Hanahan. 1996. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest. 97:54-64.
30. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol, 156: 693-699.
31. Zitvogel, L., H. Tahara, P. D. Robbins, W. J. Storkus, M. R. Clarke, M. A. Nalesnik, and M. T. Lotze. 1995. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393-1403.
32. Yu, W. G., N. Yamamoto, H. Takenaka, J. Mu, X. G. Tai, J. P. Zou, M. Ogawa, T. Tsutsui, R. Wijesuriya, R. Yoshida, S. Herrmann, H. Fujiwara, and T. Hamaoka. 1996. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. 8:855-865.
33. Houghton, A. N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
34. Kappler, J. W., N. Roehm, and P. Marrack, 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273-280.
35. Heath, W. R., J. Allison, M. W. Hoffmann, G. Schonrich, G. Hammerling, B. Arnold, and J. F. Miller. 1992. Autoimmune diabetes as a consequence of locally produced interleukin-2. Nature 359:547-549.
36. Heath, W. R., L. Kjer-Nielsen, and M. W. Hoffmann. 1993. Avidity for antigen can influence the helper dependence of CD8+ T lymphocytes. J. Immunol. 151:5993-6001.
37. Heath, W. R., F. Karamalis, J. Donoghue, and J. F. Miller. 1945. Autoimmunity caused by ignorant CD8+ T cells is transient and depends on avidity. J. Immunol. 155:2339-2349.
38. Jarnicki, A. G., D. R. Fitzpatrick, B. W. Robinson, and H. Bielefeldt-Ohmann. 1996. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma. Cancer Lett. 103:1-9.
39. Ruggiero, V., J. Tavernier, W. Fiers, and C. Baglioni. 1986. Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J. Immunol. 136:2445-2450.
40. Wallach, D., M. Fellous, and M. Revel. 1982. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 299:833-836.
41. Stuehr, D. J., and M. A. Marletta. 1987. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J. Immunol. 139:518-525.
42. Stuehr, D. J., and C. F. Nathan. 1989. Nitric oxide: a macrophage product responsible for cytoslasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169:1543-1555.
43. Farias-Eisner, R., M. P. Sherman, E. Aeberhard, and G. Chaudhuri. 1994. Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc. Nat. Acad. Sci. USA 91:9407-9411.
44. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. 1L-12 induces T helper I-directed antitumor response. J. Immunol. 158: 3359-3365.
45. Wigginton, J. M., D. B. Kuhns, T. C. Back, M. J. Brunda, R. H. Wiltrout, and G. W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131-1136.
46. Luster, A. D., and J. V. Ravetch. 1987. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166:1084-1097.
47. Farber, J. M. 1997, Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61:246-257.
48. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human inter-feron-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155-162.
49. Sgadari, C., A. L. Angiolillo, and G. Tosato, 1996. Inhibition of angiogenesis by interleukin-12 is mediated hy the interferon-inducible protein 10. Blood 87:3877-3882.
50. Brunda, M. J., and R. B. Wright. 1986. Differential antiproliferative effects of combinations of recombinant interferons alpha and gamma on two murine tumor cell lines. Int. J. Cancer 37:287-291.
51. Sugarman, B. J., B. B. Aggarwal, P. E. Hass, I. S. Figari, M. Palladino, Jr., and H. M. Shepard. 1985. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230:943-945.